Literature DB >> 24916890

A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.

Zhi-Yuan Chen1, Wen-Zhuo He, Li-Xia Peng, Wei-Hua Jia, Rong-Ping Guo, Liang-Ping Xia, Chao-Nan Qian.   

Abstract

We aimed to determine the prognostic values of 39 circulating cytokines in Chinese patients with metastatic colorectal cancer (CRC) and to develop a novel cytokine-based prognostic classifier (CBPC) for prognostic prediction. A total of 176 patients were divided into two cohorts based on the date of first-line chemotherapy. The first 99 cases were assigned to the training cohort, and the remaining 77 cases were assigned to the validation cohort. Thirty-nine cytokines were simultaneously analyzed in the patient serum samples using multiplex bead-based Luminex technology. We used support vector machine-based methods and Cox proportional hazards models to develop a CBPC from the training cohort, which we then validated using the second patient cohort. Univariate analysis showed that FGF-2, TGFα, Flt-3L, GM-CSF, INFα2, GRO, IL-10, MCP-3, MDC, sIL-2Rα, IL-2, IL-7, IL-8, MCP-1, MIP-1β, TNFα and VEGF were significant risk factors affecting the overall survival (OS) of both the training cohort and the validation cohort. We developed a CBPC to predict the OS of metastatic CRC patients using these 17 cytokines (sensitivity, 0.835; specificity, 0.800). In the validation cohort, the CBPC was found to have significant power in predicting the OS of metastatic CRC patients. Our study showed that there were significant associations between cytokine expression and prognosis of the patients with metastatic CRC. The CBPC that we developed includes multiple circulating cytokines and may serve as a novel screening tool for identifying metastatic CRC patients with a high risk of short OS. These high-risk individuals may also be suitable for cytokine-targeted therapies.
© 2014 UICC.

Entities:  

Keywords:  IL-8; MCP-1; colorectal cancer; cytokine; metastasis; overall survival; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24916890     DOI: 10.1002/ijc.29017

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Association of serum cytokines with colorectal polyp number and type in adult males.

Authors:  Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  Eur J Cancer Prev       Date:  2016-05       Impact factor: 2.497

2.  Serum cytokine profile as a potential prognostic tool in colorectal cancer patients - one center study.

Authors:  Paulina Czajka-Francuz; Tomasz Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Marcin Fajkis; Bożena Szymczak; Maciej Kozaczka; Krzysztof Piotr Malinowski; Wojciech Zasada; Jerzy Wojnar; Jerzy Chudek
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-21

Review 3.  Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Valentina Russo; Eleonora Lallo; Armelle Munnia; Miriana Spedicato; Luca Messerini; Romina D'Aurizio; Elia Giuseppe Ceroni; Giulia Brunelli; Antonio Galvano; Antonio Russo; Ida Landini; Stefania Nobili; Marcello Ceppi; Marco Bruzzone; Fabio Cianchi; Fabio Staderini; Mario Roselli; Silvia Riondino; Patrizia Ferroni; Fiorella Guadagni; Enrico Mini; Marco Peluso
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

4.  A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.

Authors:  Andrew Mitchell; Sarrah L Hasanali; Daley S Morera; Rohitha Baskar; Xin Wang; Rahil Khan; Asif Talukder; Charles S Li; Meenakkshy Manoharan; Andre R Jordan; Jiaojiao Wang; Roni J Bollag; Nagendra Singh; Daniel Albo; Santu Ghosh; Vinata B Lokeshwar
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

5.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial.

Authors:  Vitaly Margulis; Yuval Freifeld; Laurentiu M Pop; Subrata Manna; Payal Kapur; Ivan Pedrosa; Alana Christie; Osama Mohamad; Samantha Mannala; Nirmish Singla; Michael Wait; Aditya Bagrodia; Solomon L Woldu; Jeffrey Gahan; James Brugarolas; Robert Timmerman; Raquibul Hannan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-02-05       Impact factor: 8.013

7.  Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis.

Authors:  Wenjie Xia; Wuzhen Chen; Zhigang Zhang; Dang Wu; Pin Wu; Zhigang Chen; Chao Li; Jian Huang
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

8.  Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.

Authors:  Giuseppe Di Caro; Michele Carvello; Samantha Pesce; Marco Erreni; Federica Marchesi; Jelena Todoric; Matteo Sacchi; Marco Montorsi; Paola Allavena; Antonino Spinelli
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

Review 9.  Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays.

Authors:  Francesca Capone; Eliana Guerriero; Angela Sorice; Giovanni Colonna; Gennaro Ciliberto; Susan Costantini
Journal:  Mediators Inflamm       Date:  2016-12-06       Impact factor: 4.711

10.  -2518 A/G MCP-1 but not -403 G/A RANTES gene polymorphism is associated with enhanced risk of basal cell carcinoma.

Authors:  Michał Sobjanek; Monika Zabłotna; Aneta Szczerkowska-Dobosz; Katarzyna Ruckemann-Dziurdzińska; Malgorzata Sokolowska-Wojdylo; Roman Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2016-10-21       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.